ECM
INBX

Endurant Capital Management’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Endurant Capital Management’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-13,485
Closed -$332K – 70
2022
Q4 		$332K Buy
+13,485
New +$396K 0.13% 50
2020
Q4 		– Sell
-35,935
Closed -$647K – 81
2020
Q3 		$647K Buy
+35,935
New +$651K 0.19% 56

Other funds holding INBX

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Endurant Capital Management's INBX Position: Q1 2023 in Review

Endurant Capital Management sold out of Inhibrx, Inc. Common Stock (INBX) in Q1 2023, closing a stake of 13,485 shares — an estimated $332K sold.

Endurant Capital Management first reported a position in INBX in Q3 2020 and held it in 2 quarters. The position peaked at $647K in Q3 2020. 108 funds tracked by Wall St. Rank hold INBX as of Q1 2023.

  • Endurant Capital Management reported no remaining Inhibrx, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Endurant Capital Management sold 13,485 Inhibrx, Inc. Common Stock shares in Q1 2023, an estimated $332K.
  • Endurant Capital Management first reported a position in Inhibrx, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
  • Endurant Capital Management's Inhibrx, Inc. Common Stock position peaked at $647K in Q3 2020.
  • 108 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q1 2023.

Based on Endurant Capital Management's 13F filing for Q1 2023, filed 15 May 2023.